 | | Vol. 12.05 – 9 February, 2023 |
| |
|
|
| Scientists showed that 8-oxoguanine DNA glycosylase-1 (Ogg1)-targeting siRNA mitigated bleomycin-induced pulmonary fibrosis in male mice, highlighting OGG1 as a tractable target in lung fibrosis.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers provided insight into how fibroblasts gained resistance to apoptosis and became sensitive to the therapeutic inhibition of antiapoptotic proteins.
[Jci Insight] |
|
|
|
| Investigators raised the possibility that the squamous differentiation naturally occurring in healthy airways identified herein may represent “vulnerable spots” within the airway mucosa that were sensitive to damage and inflammation when confronted by infection or injury.
[American Journal Of Respiratory Cell And Molecular Biology] |
|
|
|
| Scientists investigated whether centrosome clustering inhibition would preferentially radiosensitize NSCLC.
[Molecular Cancer Therapeutics] |
|
|
|
| Researchers identified osa-miR172d-5p, a plant-derived microRNA (miR), as a potent anti-fibrotic miR. In silico analysis followed by an in vitro assay based on human lung fibroblasts demonstrated that osa-miR172d-5p suppressed the gene expression of TGF-β activated kinase 1 binding protein 1 (Tab1).
[Scientific Reports] |
| |
|
|
| Investigators used three murine models of EML4-ALK lung cancer to test the role of host immunity in the alectinib therapeutic response.
[Npj Precision Oncology] |
|
|
|
| The authors described the design and development of third-generation mutant-selective epidermal growth factor receptor (EGFR) inhibitors with improved in vitro and in vivo profiles and lower toxicities during administration to patients than those of previously disclosed second-generation furanopyrimidine EGFR inhibitors.
[Journal Of Medicinal Chemistry] |
|
|
|
| Scientists examined a chemo-resistant SCLC cell line using genome-wide CRISPR/Cas9 screening and identified serine/threonine kinase cell division cycle 7 (CDC7) as a potential synergistic target.
[Cell Death Discovery] |
|
|
|
| Researchers revealed the regulatory effects and molecular mechanism of circANKRD28 on the development and cisplatin resistance in NSCLC, which may provide an experimental basis and theoretical support to identify new targets for the therapy of DDP resistance NSCLC.
[The Journal Of Gene Medicine] |
|
|
|
|
| | The current challenges and potential strategies toward truly biomimetic lung models are discussed.[Advanced Materials] |
|
|
|
| The authors summarize recent therapeutic advances in targeting human epidermal growth factor receptor 2 (HER2) alterations in NSCLC and highlight the future perspectives of retreated HER2-mutant patient populations.
[Cancer Treatment Reviews] |
|
|
|
|
| The collaboration focused on the advancement of Ankyra’s lead product candidate, ANK-101, an IL-12-based locally administered immunotherapy, as a potential treatment for lung cancer.
[Ankyra Therapeutics] |
|
|
|
| Oncotelic Therapeutics, Inc announced the initiation of its second investigator-initiated study in a series of planned clinical studies.
[Oncotelic Therapeutics, Inc.] |
|
|
|
|
| February 22 – 23, 2023
Boston, Massachusetts, United States |
|
|
|
|
|
| | Emory University – Atlanta, Georgia, United States |
|
|
|
| | AstraZeneca – Cambridge, England, United Kingdom |
|
|
|
| | STEMCELL Technologies – Vancouver, British Columbia, Canada |
|
|
|
| | IRCCS Candiolo Cancer Institute – Turin, Italy |
|
|
|
| | Pompeu Fabra University – Barcelona, Spain |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
